We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Functional precision medicine demonstrates the therapeutic efficacy of bortezomib in relapsed/refractory sarcoma, suggesting potential benefits for targeted treatment.
7.5%.Other G1/2: mucositis 37.5%, hyperglycemia 37
No takes yet. Share an insight, caveat, or question.
Poon et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: